Results 201 to 210 of about 6,471,944 (292)

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem   +5 more
wiley   +1 more source

Extrapolation and pharmacokinetic protocol design optimization for ceftriaxone as an exemplar for the development of antibiotics for children

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Ceftriaxone is a cephalosporin commonly used for the treatment of acute, severe infections; however, there are conflicting data on its disposition properties in children, making it a suitable case study for the evaluation of the appropriateness of extrapolation approaches based on exposure matching principles for paediatric patients and exploring ...
Daniel Valente Neves   +7 more
wiley   +1 more source

Cefepime exposure in prolonged or intermittent infusion in critically ill children

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient.
Marc Hobeika   +12 more
wiley   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling   +6 more
wiley   +1 more source

Clinical Images: A thorn injury, a sea‐borne culprit, and a tenosynovitis dilemma

open access: yes
Arthritis &Rheumatology, EarlyView.
Jacopo Ciaffi   +8 more
wiley   +1 more source

Magnetoelastic Cell Monitoring System for Evaluating the Effects of Surface Chemistry on the Performance of Mesenchymal Stem Cell Growth

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT The recent clinical adoption of cell therapies has increased the need for more efficient, robust, and reproducible manufacturing technologies. Human mesenchymal stromal cells (hMSCs), a major component of the cell and immunotherapeutic market, remain challenging to manufacture at scale because they require surface attachment and are highly ...
William S. Skinner   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy